BioCentury | Apr 15, 2021
Regulation

April 14 Quick Takes: GSK stops two trials of ICOS agonist; plus Trodelvy, Amylyx, Junshi, Jazz, MitoChem

...latest approval is for adults who have previously received a platinum-containing chemotherapy and either a PD-1...
...41% reduction in upper limb tremor amplitude compared with baseline.Expanded label in China for Junshi’s PD-1...
...and NIH.TARGETSICOS –Inducible T cell co-stimulatorPD-1 (PDCD1; CD279) –Programmed cell death 1PD-L1 (B7-H1; CD274) – Programmed cell death 1...
BioCentury | Apr 13, 2021
Product Development

FDA requests more data from Provention; plus Iterum, Seagen-Genmab, Pfizer and Gilead

Shares of Provention Bio Inc. (NASDAQ:PRVB) regained a small bit of the ground they lost Friday, when the stock tumbled 18% to $8 after the company revealed FDA wants more data on its BLA for...
BioCentury | Apr 12, 2021
Product Development

AACR data suggest Agenus’ next-generation CTLA-4 blocker may expand responding patient group

...treat patients who don’t respond to first-generation PD-1...
...the combination arm with the company’s clinical PD-1...
BioCentury | Apr 10, 2021
Product Development

Bispecific constructs move beyond T cell engagers at AACR

...–Tumor necrosis factor receptor superfamily member 4PD-1 (PDCD1; CD279) –Programmed cell death 1PD-L1 (B7-H1; CD274) –Programmed cell death 1...
BioCentury | Apr 7, 2021
Distillery Therapeutics

CXCR4 antagonist identified for hepatocellular carcinoma

...liver fibrosis, the CXCR4 antagonist plus an anti-PD-1...
BioCentury | Apr 6, 2021
Distillery Therapeutics

Targeting ferroptosis directly or via CD36 inhibition for melanoma, MM, NSCLC

...transfer of CD36-knockout CD8+ T cells plus an anti-PD-1...
BioCentury | Apr 3, 2021
Product Development

Target diversity in the CAR NK and CAR NKT pipeline: Data Byte

...receptor 2NKG2D (KLRK1; CD314) – Killer cell lectin-like receptor subfamily K member 1PD-L1 (B7-H1; CD274) – Programmed cell death 1...
BioCentury | Mar 27, 2021
Regulation

March 26 Quick Takes: ADCs from Astellas-Seagen, Gilead under EMA review; plus Pfizer-Lilly, BrainStorm and Ilya

...conjugate (ADC) targeting PRR4, to treat locally advanced or metastatic urothelial cancer previously treated with a PD-1/PD-L1...
BioCentury | Mar 27, 2021
Translation in Brief

Lentigen’s trispecific CAR Ts; plus a bispecific antiviral COVID-19 mAb, Wild Biotech, Kancera and more

...They reported in Science Advances that, when added to anti-PD-1...
...CX3C motif receptor 1PD-1 (PDCD1; CD279) – Programmed cell death 1 VEGF-C...
...Biotech Ltd. Vascular endothelial growth factor C (VEGF-C) (VRP) Programmed cell death 1 (PD-1) (PDCD1) (CD279) Chemokine...
BioCentury | Mar 26, 2021
Product Development

Next-generation checkpoint development surges as rare wins overshadow setbacks

...search for a safe and effective agent.After PD-1...
...superfamily member 4OX40L (CD134L) –OX40 ligandPD-1 (PDCD1; CD279...
...CD279) –Programmed cell death 1PD-L1 (B7-H1; CD274) –Programmed cell death 1...
Items per page:
1 - 10 of 4970